CD8A and neoplasm: When injected with cas9/sgRNA, PD-1 aptamers could be precisely released via cas9 mediated cleavage, followed by binding with PD-1 on CD8+ T cells to block the immune checkpoint, thereby enhancing the vitality of CD8+ T cells to kill tumor cells.